Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients

Ozsahin, Mahmut; Tsang, Richard W; Poortmans, Philip; Belkacémi, Yazid; Bolla, Michel; Dinçbas, Fazilet Oner; Landmann, Christine; Castelain, Bernard; Buijsen, Jeroen; Curschmann, Jürgen; Kadish, Sidney P; Kowalczyk, Anna; Anacak, Yavuz; Hammer, Josef; Nguyen, Tan D; Studer, Gabriela; Cooper, Rachel; Sengöz, Meriç; Scandolaro, Luciano and Zouhair, Abderrahim (2006). Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. International journal of radiation oncology, biology, physics, 64(1), pp. 210-7. New York, N.Y.: Elsevier 10.1016/j.ijrobp.2005.06.039

Full text not available from this repository. (Request a copy)

PURPOSE: To assess the outcomes and patterns of failure in solitary plasmacytoma (SP). METHODS AND MATERIALS: The data from 258 patients with bone (n = 206) or extramedullary (n = 52) SP without evidence of multiple myeloma (MM) were collected. A histopathologic diagnosis was obtained for all patients. Most (n = 214) of the patients received radiotherapy (RT) alone; 34 received chemotherapy and RT, and 8 surgery alone. The median radiation dose was 40 Gy. The median follow-up was 56 months (range 7-245). RESULTS: The median time to MM development was 21 months (range 2-135), with a 5-year probability of 45%. The 5-year overall survival, disease-free survival, and local control rate was 74%, 50%, and 86%, respectively. On multivariate analyses, the favorable factors were younger age and tumor size <4 cm for survival; younger age, extramedullary localization, and RT for disease-free survival; and small tumor and RT for local control. Bone localization was the only predictor of MM development. No dose-response relationship was found for doses >30 Gy, even for larger tumors. CONCLUSION: Progression to MM remains the main problem. Patients with extramedullary SP had the best outcomes, especially when treated with moderate-dose RT. Chemotherapy and/or novel therapies should be investigated for bone or bulky extramedullary SP.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Curschmann, Jürgen










Factscience Import

Date Deposited:

04 Oct 2013 14:48

Last Modified:

05 Dec 2022 14:14

Publisher DOI:


PubMed ID:


Web of Science ID:



https://boris.unibe.ch/id/eprint/19936 (FactScience: 3014)

Actions (login required)

Edit item Edit item
Provide Feedback